keyword
MENU ▼
Read by QxMD icon Read
search

bisphosphonates pain

keyword
https://www.readbyqxmd.com/read/28078129/osteonecrosis-of-the-jaw-associated-with-ziv-aflibercept
#1
Hani Mawardi, Peter Enzinger, Nadine McCleary, Reshma Manon, Alessandro Villa, Nathaniel Treister, Sook-Bin Woo
Medication-related osteonecrosis of the jaw (MRONJ) has been associated with medications that include bisphosphonates (BPs), denosumab, bevacizumab and sunitinib. Ziv-aflibercept is a recombinant human vascular endothelial growth factor (VEGF) receptor which has been used to treat patients with various advanced solid tumors. We report three patients without a history of the use of medications known to cause MRONJ presenting with jaw osteonecrosis typical for MRONJ following therapy with ziv-aflibercept. All patients had metastatic gastrointestinal cancer treated with ziv-aflibercept and were evaluated for MRONJ because of exposed bone in the oral cavity...
December 2016: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28057402/consultation-with-a-specialized-pain-clinic-reduces-pain-after-oral-and-maxillofacial-surgery
#2
Eva-Maria Dietrich, Norbert Griessinger, Friedrich Wilhelm Neukam, Tilo Schlittenbauer
PURPOSE: Postoperative pain management is important for improved patient care. Our primary objective was to investigate the effect of analgesic treatment adaptation by the pain clinic on postoperative pain relief at an oral and maxillofacial surgery department. Additionally, we aimed to present patients' pain characteristics and the administered analgesic treatment. MATERIALS AND METHODS: A total of 128 patients treated at our clinic in the period 2012-2015 who required analgesic treatment adaptation by our pain clinic were included...
December 14, 2016: Journal of Cranio-maxillo-facial Surgery
https://www.readbyqxmd.com/read/28051824/atypical-femoral-fracture-as-first-sign-of-non-hodgkin-lymphoma-case-report-with-a-brief-review-of-the-literature
#3
G Saviola, P Prometti, P R Ferrari, L G Dalle Carbonare
ABSTRACT: Atypical subtrochanteric and diaphyseal femoral fractures (AFF) have been suggested to be associated with the use of bisphosphonates (BPs), but the role of these drugs is still under debate. A 64-year old female, never treated with BPs was admitted to our Rehabilitation Institute because of a recent right AFF. The patient began suffering from low back pain radiating to the groin and to the anterior regions of the right thigh and leg, A nuclear magnetic resonance (NMR) of the lumbar spine showed disc protrusions at the L3-L4 and L5-S1 levels with impingement of the spinal nerve root...
November 2016: La Clinica Terapeutica
https://www.readbyqxmd.com/read/28039445/aromatase-inhibitor-induced-bone-loss-increases-the-progression-of-estrogen-receptor-negative-breast-cancer-in-bone-and-exacerbates-muscle-weakness-in-vivo
#4
Laura E Wright, Ahmed A Harhash, Wende M Kozlow, David L Waning, Jenna N Regan, Yun She, Sutha K John, Sreemala Murthy, Maryla Niewolna, Andrew R Marks, Khalid S Mohammad, Theresa A Guise
Aromatase inhibitors (AIs) cause muscle weakness, bone loss, and joint pain in up to half of cancer patients. Preclinical studies have demonstrated that increased osteoclastic bone resorption can impair muscle contractility and prime the bone microenvironment to accelerate metastatic growth. We hypothesized that AI-induced bone loss could increase breast cancer progression in bone and exacerbate muscle weakness associated with bone metastases. Female athymic nude mice underwent ovariectomy (OVX) or sham surgery and were treated with vehicle or AI (letrozole; Let)...
December 25, 2016: Oncotarget
https://www.readbyqxmd.com/read/28031516/review-article-osteophytes
#5
Siu Him Janus Wong, Kwong Yuen Chiu, Chun Hoi Yan
An osteophyte is a fibrocartilage-capped bony outgrowth that is one of the features of osteoarthritis. This study reviewed the types, risk factors, pathophysiology, clinical presentations, and medical and surgical treatment of osteophytes. Extraspinal osteophytes are classified as marginal, central, periosteal, or capsular, whereas vertebral osteophytes are classified as traction or claw. Risk factors for development of osteophytes include age, body mass index, physical activity, and other genetic and environmental factors...
December 2016: Journal of Orthopaedic Surgery
https://www.readbyqxmd.com/read/28008379/a-phase-2-trial-exploring-the-clinical-and-correlative-effects-of-combining-doxycycline-with-bone-targeted-therapy-in-patients-with-metastatic-breast-cancer
#6
C L Addison, D Simos, Z Wang, G Pond, S Smith, S Robertson, S Mazzarello, G Singh, L Vandermeer, R Fernandes, A Iyengar, S Verma, M Clemons
BACKGROUND: Bone-targeting agents (BTAs), such as bisphosphonates and denosumab, have demonstrated no discernable effects on tumour response or disease free/overall survival in patients with bone metastases from breast cancer. Doxycycline is both osteotropic and has anti-cancer effects. When combined with zoledronate in animal models, doxycycline showed significantly increased inhibition of tumour burden and increased bone formation. We evaluated the effects of adding doxycycline to ongoing anti-cancer therapy in patients with metastatic breast cancer...
November 2016: Journal of Bone Oncology
https://www.readbyqxmd.com/read/28007291/-complex-regional-pain-syndrome-a-review
#7
Berenice Carolina Hernández-Porras, Ricardo Plancarte-Sánchez, Silvia Alarcón-Barrios, Marcela Sámano-García
BACKGROUND: Complex regional pain syndrome is characterized by spontaneous or induced pain disproportionate in relation to the initial event and is accompanied by a variety of regional and motor disturbances, leading to a variety of clinical presentations. It is often associated with surgery and minor trauma. PATHOPHYSIOLOGY: Three mechanisms are postulated: changes secondary to post traumatic inflammation, peripheral vasomotor dysfunction and structural and functional changes of the central nervous system as a result of maladaptation...
December 19, 2016: Cirugia y Cirujanos
https://www.readbyqxmd.com/read/27984770/improving-quality-of-life-in-patients-with-advanced-cancer-targeting-metastatic-bone-pain
#8
REVIEW
Roger von Moos, Luis Costa, Carla Ida Ripamonti, Daniela Niepel, Daniele Santini
Metastatic bone disease in patients with advanced cancer is frequently associated with skeletal complications. These can be debilitating, causing pain, impaired functioning and decreased quality of life, as well as reduced survival. This review considers how the management of metastatic bone pain might be optimised, to limit the considerable burden it can impose on affected patients. Cancer-related pain is notoriously under-reported and under-treated, despite the availability of many therapeutic options. Non-opioid and opioid analgesics can be used; the latter are typically administered with radiotherapy, which forms the current standard of care for patients with metastatic bone pain...
January 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/27979741/complex-regional-pain-syndrome-type-i-in-children-what-is-new
#9
REVIEW
P Lascombes, C Mamie
Complex regional pain syndrome type I (CRPS-I), although first described by the French surgeon Ambroise Paré as far back as the 16th century, nevertheless remains shrouded in mystery. The most common symptoms are pain in an entire hand or foot, allodynia, functional impairment induced by the pain, local oedema and skin color changes and transient sweating abnormalities. Most cases occur after a minor injury (i.e., a sprain or fracture), although there may be no identifiable triggering event, particularly in children...
December 12, 2016: Orthopaedics & Traumatology, Surgery & Research: OTSR
https://www.readbyqxmd.com/read/27939801/first-cases-of-calcium-pyrophosphate-deposition-disease-after-zoledronic-acid-therapy
#10
Guillaume Couture, Faustine Delzor, Haleh Bagheri, Joëlle Micallef, Adeline Ruyssen-Witrand, Michel Laroche
A number of medications promote the development of calcium pyrophosphate deposition disease (CPDD). We report 2 cases of acute CPDD after intravenous zoledronic acid therapy. Case #1: a 63-year-old female was admitted for vertebroplasty at the site of an osteoporotic fracture. She received an intravenous infusion of zoledronic acid 5mg on the day after the procedure. Acute CPDD developed in her right knee 24hours later. Findings from joint aspiration and standard radiography confirmed the diagnosis. Case #2: this 79-year-old woman had a history of CPDD was on glucocorticoid and hydroxychloroquine therapy for lupus...
December 6, 2016: Joint, Bone, Spine: Revue du Rhumatisme
https://www.readbyqxmd.com/read/27933174/a-case-of-hepatitis-c-associated-osteosclerosis-accelerated-bone-turnover-controlled-by-pulse-steroid-therapy
#11
Nobuhiro Miyamura, Shuhei Nishida, Mina Itasaka, Hirofumi Matsuda, Takeshi Ohtou, Yasuhiro Yamaguchi, Daisuke Inaba, Sadahiro Tamiya, Tetsuo Nakano
: Hepatitis C-associated osteosclerosis (HCAO), a very rare disorder in which an extremely rapid bone turnover occurs and results in osteosclerosis, was acknowledged in 1990s as a new clinical entity with the unique bone disorder and definite link to chronic type C hepatitis, although the pathogenesis still remains unknown. Affected patients suffer from excruciating deep bone pains. We report the 19th case of HCAO with diagnosis confirmed by bone biopsy, and treated initially with a bisphosphonate, next with corticosteroids and finally with direct acting antivirals (DAA: sofosbuvir and ribavirin) for HCV infection...
2016: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/27866217/osteonecrosis-of-the-jaw-onj-and-atypical-femoral-fracture-aff-in-an-osteoporotic-patient-chronically-treated-with-bisphosphonates
#12
A Sánchez, R Blanco
The aim of the study is to report the rare association of two complications of long-term treatment of osteoporosis with bisphosphonates in the same Caucasian elderly patient. A female patient of Italian descent, age 87 years, consulted in February 2013. She had a history of osteoporosis and had taken alendronate weekly for 7 years (1999-2006). Due to low back pain, an orthopedist had indicated i.v. zoledronic acid, 5 mg/year for 3 years (2006-2008). She received occasional supplements of ergocalciferol...
November 20, 2016: Osteoporosis International
https://www.readbyqxmd.com/read/27863287/bone-health-in-the-elderly-cancer-patient-a-siog-position-paper
#13
REVIEW
J J Body, E Terpos, B Tombal, P Hadji, A Arif, A Young, M Aapro, R Coleman
More than a third of cancers are diagnosed in people over the age of 75. Androgen deprivation for prostate cancer and aromatase inhibitors in breast cancer accelerate age-related bone loss and increase fracture rates. BMD should be checked by dual energy X-ray absorptiometry at baseline and, dependent on risk, every 12-24months. Sufficient calcium, vitamin D and exercise are part of primary fracture prevention. Resistance exercise in particular may improve functional activity and bone density. In men at increased fracture risk and women with postmenopausal early breast cancer, antiresorptive treatment is warranted to reduce fracture rate and to increase overall survival in breast cancer...
December 2016: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/27862203/production-quality-control-and-determination-of-human-absorbed-dose-of-no-carrier-added-177-lu-risedronate-for-bone-pain-palliation-therapy
#14
Nafise Salek, Mohsen Mehrabi, Simindokht Shirvani Arani, Ali Bahrami Samani, Mostafa Erfani, Sara Vosoghi, Mohammad Ghannadi Maragheh, Mojtaba Shamsaei
In this study, the radiocomplexation of risedronic acid, a potent bisphosphonate with a no carrier added (NCA) (177) Lu, was investigated and followed by quality control studies, biodistribution evaluation, and dosimetry study for human based on biodistribution data in Wistar rats. The moderate energy β(-) emitter, (177) Lu (T½  = 6.7 days, Eβmax  = 497 keV), has been considered as a potential agent for development of bone-seeking radiopharmaceuticals. Because the specific activity of the radiolabeled carrier molecules should be high, the NCA radionuclides have an effective role in nuclear medicine...
November 15, 2016: Journal of Labelled Compounds & Radiopharmaceuticals
https://www.readbyqxmd.com/read/27843872/an-unusual-presentation-of-metastatic-bone-disease-in-a-subject-with-paget-s-disease-of-bone
#15
Shrinath Shetty, Sahana Shetty, Annie Jennifer Prabhu, Nitin Kapoor, Julie Hepzibah, Thomas Vizhalil Paul
Solid organ malignancies involving breast, prostate, and lung frequently metastasize to the skeleton. However, the occurrence of Paget's disease and metastatic bone disease in the same patient is uncommon. We report a case of a 63-year-old man who presented with back pain and a lump in the right breast. He was earlier diagnosed to have Paget's disease of bone based on characteristic skeletal radiological features,(99m)Tc methylene diphosphonate bone scan and elevated alkaline phosphatase, and treated with bisphosphonates, and his disease was in remission...
April 2016: Journal of Family Medicine and Primary Care
https://www.readbyqxmd.com/read/27824547/atypical-femur-fractures-in-patients-treated-with-bisphosphonates-identification-management-and-prevention
#16
REVIEW
Judith Sarah Bubbear
Osteoporosis is a common condition with significant health care costs. First-line therapy is with bisphosphonates, which have proven anti-fracture efficacy. Around 10 years after the introduction of bisphosphonates reports began to be published of atypical femoral fractures (AFFs) that may be associated with this therapy. These fractures are associated with significant morbidity although lower mortality than the more common osteoporotic neck-of-femur fractures. A case definition has been described to allow identification of this class of fracture...
October 31, 2016: Rambam Maimonides Medical Journal
https://www.readbyqxmd.com/read/27822735/successful-treatment-of-chronic-recurrent-multifocal-osteomyelitis-using-low-dose-radiotherapy-a-case-report
#17
Christian T Dietzel, Christoph Schäfer, Dirk Vordermark
BACKGROUND: Chronic recurrent multifocal osteomyelitis (CRMO) is a rare autoinflammatory disease, which lacks an infectious genesis and predominantly involves the metaphysis of long bones. Common treatments range from nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids at first onset of disease, to immunosuppressive drugs and bisphosphonates in cases of insufficient remission. The therapeutic use of low-dose radiotherapy for CRMO constitutes a novelty. CASE REPORT: A 67-year-old female patient presented with radiologically proven CRMO affecting the right tibia/talus and no response to immunosuppressive therapy...
November 7, 2016: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/27813341/pharmacological-and-biological-therapeutic-strategies-for-osteogenesis-imperfecta
#18
REVIEW
Ronit Marom, Yi-Chien Lee, Ingo Grafe, Brendan Lee
Osteogenesis imperfecta (OI) is a connective tissue disorder characterized by bone fragility, low bone mass, and bone deformities. The majority of cases are caused by autosomal dominant pathogenic variants in the COL1A1 and COL1A2 genes that encode type I collagen, the major component of the bone matrix. The remaining cases are caused by autosomal recessively or dominantly inherited mutations in genes that are involved in the post-translational modification of type I collagen, act as type I collagen chaperones, or are members of the signaling pathways that regulate bone homeostasis...
December 2016: American Journal of Medical Genetics. Part C, Seminars in Medical Genetics
https://www.readbyqxmd.com/read/27760454/bisphosphonate-therapy-for-osteogenesis-imperfecta
#19
REVIEW
Kerry Dwan, Carrie A Phillipi, Robert D Steiner, Donald Basel
BACKGROUND: Osteogenesis imperfecta is caused by a genetic defect resulting in an abnormal type I collagen bone matrix which typically results in multiple fractures with little or no trauma. Bisphosphonates are used in an attempt to increase bone mineral density and reduce these fractures in people with osteogenesis imperfecta. This is an update of a previously published Cochrane Review. OBJECTIVES: To assess the effectiveness and safety of bisphosphonates in increasing bone mineral density, reducing fractures and improving clinical function in people with osteogenesis imperfecta...
October 19, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27759649/erdheim-chester-disease-ecd-case-report-clinical-and-basic-investigations-and-review-of-literature
#20
Mohammad Adawi, Bishara Bisharat, Abdalla Bowirrat
BACKGROUND: Erdheim-Chester disease (ECD) is an uncommon aggressive, multisystem form of non-Langerhans' cell histocytosis, which was firstly reported by Jakob Erdheim and William chester in 1930. The disease pathological features encompass an aberrant multiplication, overproduction and accumulation of white blood cells called histiocytes within multiple tissues and organs. Herein, we present a case of ECD owing to the rarity of this disease (roughly 550 cases have been described in the literature to date)...
October 2016: Medicine (Baltimore)
keyword
keyword
75048
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"